Form 4: KALA BIO CEO's Convertible Loan Repaid in Cash

KALA BIO, Inc. CEO David E. Lazar's convertible loan of up to $375,000 was fully repaid in cash by the issuer on December 18, 2025, foregoing conversion into common stock.

Summary

• David E. Lazar, Chief Executive Officer and Director of KALA BIO, Inc. (KALA), reported a transaction involving a convertible loan.
• On November 9, 2025, Lazar, as 'Lender', entered into a Convertible Loan Agreement with KALA BIO, Inc., agreeing to loan the Issuer up to $375,000.
• The agreement granted Lazar the discretion to convert the outstanding loan amount into KALA BIO's common stock at a 'Conversion Price' of $1.017 per share.
• On December 18, 2025, KALA BIO, Inc. fully repaid the entire Loan Amount to David E. Lazar in cash.
• Following the repayment, Lazar beneficially owns 0 shares of common stock and 0 derivative securities related to this specific convertible loan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The repayment of the loan in cash is a routine financial event that avoids potential shareholder dilution, which is a positive. However, the CEO not converting to equity could be seen as a neutral or slightly less positive signal regarding direct equity commitment.

Positives

• The full repayment of the convertible loan in cash by KALA BIO, Inc. avoids potential dilution for existing shareholders that would have occurred if the loan had been converted into common stock.
• The company's ability to repay the loan in cash suggests a stable financial position regarding this specific obligation.

Negatives

• The repayment means David E. Lazar did not increase his direct equity stake in the company through the conversion of this loan, which could be interpreted as a missed opportunity for the CEO to show further long-term commitment via equity ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• David E. Lazar, as 'Lender', entered into a Convertible Loan Agreement with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000.
• Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the 'Conversion Price'.

Industry Context

This Form 4 reports a specific insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• David E. Lazar, as CEO and Director of KALA BIO, Inc., entered into a Convertible Loan Agreement with the company, lending it up to $375,000. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Avoided potential dilution from the conversion of the loan into common stock.
• Company: Fulfilled a financial obligation by repaying the loan in cash.

Key Dates

Recommendation

This Form 4 reports a routine repayment of a convertible loan by the company to its CEO. While it avoids potential dilution, it does not introduce new information that would fundamentally alter the investment thesis for KALA BIO, Inc. Therefore, a 'hold' recommendation is appropriate as this transaction alone is unlikely to significantly impact the company's long-term prospects or valuation.

Keywords

KALA BIO, KALA, David E. Lazar, Convertible Loan, Loan Repayment, Insider Transaction, SEC Form 4, CEO, Director, Equity Dilution